Anti-YIPF3/ C6orf109/ FinGER3 monoclonal antibody

Anti-YIPF3/ C6orf109/ FinGER3 antibody for FACS & in-vivo assay

Target products collectionGo to YIPF3/YIPF3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1953-Ab-1/ GM-Tg-hg-MP1953-Ab-2Anti-Human YIPF3 monoclonal antibodyHuman
GM-Tg-rg-MP1953-Ab-1/ GM-Tg-rg-MP1953-Ab-2Anti-Rat YIPF3 monoclonal antibodyRat
GM-Tg-mg-MP1953-Ab-1/ GM-Tg-mg-MP1953-Ab-2Anti-Mouse YIPF3 monoclonal antibodyMouse
GM-Tg-cynog-MP1953-Ab-1/ GM-Tg-cynog-MP1953-Ab-2Anti-Cynomolgus/ Rhesus macaque YIPF3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1953-Ab-1/ GM-Tg-felg-MP1953-Ab-2Anti-Feline YIPF3 monoclonal antibodyFeline
GM-Tg-cang-MP1953-Ab-1/ GM-Tg-cang-MP1953-Ab-2Anti-Canine YIPF3 monoclonal antibodyCanine
GM-Tg-bovg-MP1953-Ab-1/ GM-Tg-bovg-MP1953-Ab-2Anti-Bovine YIPF3 monoclonal antibodyBovine
GM-Tg-equg-MP1953-Ab-1/ GM-Tg-equg-MP1953-Ab-2Anti-Equine YIPF3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1953-Ab-1/ GM-Tg-hg-MP1953-Ab-2; GM-Tg-rg-MP1953-Ab-1/ GM-Tg-rg-MP1953-Ab-2;
GM-Tg-mg-MP1953-Ab-1/ GM-Tg-mg-MP1953-Ab-2; GM-Tg-cynog-MP1953-Ab-1/ GM-Tg-cynog-MP1953-Ab-2;
GM-Tg-felg-MP1953-Ab-1/ GM-Tg-felg-MP1953-Ab-2; GM-Tg-cang-MP1953-Ab-1/ GM-Tg-cang-MP1953-Ab-2;
GM-Tg-bovg-MP1953-Ab-1/ GM-Tg-bovg-MP1953-Ab-2; GM-Tg-equg-MP1953-Ab-1/ GM-Tg-equg-MP1953-Ab-2
Products NameAnti-YIPF3 monoclonal antibody
Formatmab
Target NameYIPF3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-YIPF3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species YIPF3/ C6orf109/ FinGER3 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1953
    Target NameYIPF3
    Gene ID25844,28064,301245,700228,481817,101087742,540431,100055327
    Gene Symbol and SynonymsC6orf109,D17Wsu94e,dJ337H4.3,FinGER3,KLIP1,LRRGT00110,RGD1308185,YIPF3
    Uniprot AccessionQ9GZM5,Q6TUD4
    Uniprot Entry NameYIPF3_HUMAN,YIPF3_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000137207
    Target ClassificationN/A

    The target: YIPF3, gene name: YIPF3, also named as C6orf109, FinGER3, KLIP1, dJ337H4.3. Predicted to be involved in cell differentiation. Located in Golgi apparatus and transport vesicle. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.